Given that authorised in 2014, tucidinostat was considered as a 2nd-line and subsequent therapy for PTCL sufferers in China. Scientific trials and preclinical experiments in several hematological malignancies and good tumors is in progress. Use or redistribution of any DrugBank content or facts d